SATB2在卵巢原发腺癌和结直肠癌卵巢转移中的鉴别诊断意义

The differential significance of SATB2 in ovarian primary adenocarcinoma and colorectal carcinoma ovarian metastases

目的研究SATB2在卵巢的原发腺癌和卵巢的结直肠转移癌中的鉴别诊断意义。方法采用免疫组化的方法检测SATB2在130例结肠腺癌,53例卵巢黏液腺癌和40例卵巢的结直肠转移癌中的表达,分析SATB2的鉴别诊断作用。结果 SATB2在130例结肠腺癌中的阳性表达率为73.85%(96/130),在117例管状腺癌中的阳性表达率为72.65%(85/117),在13例黏液腺癌中的阳性表达率为84.62%(11/13)。SATB2在高分化和中分化腺癌中的表达显著高于在低分化腺癌中的表达(P <0.05)。在53例卵巢黏液腺癌中的阳性表达率为0%(0/53),在40例卵巢的结直肠转移癌中的表达率为82.50%(33/40)。结论 SATB2可作为发生在卵巢的转移性腺癌的有效肿瘤标记物,特别对于卵巢的结直肠黏液腺癌转移具有重要的鉴别诊断意义,为临床医生选择治疗方案提供理论依据。

Objective To study the differential diagnosis of SATB2 in ovarian primary adenocarcinoma and colorectal carcinoma ovarian metastases.Methods Immunohistochemistry was used to detect the expression level of SATB2 in 130 cases of colon adenocarcinoma,53 cases of ovarian mucinous adenocarcinoma and 40 cases of colorectal carcinoma ovarian metastases.Results The positive expression rate of SATB2 in 130 cases of colon adenocarcinoma was 73.85%(96/130),in 117 cases of tubular adenocarcinoma was 72.65%(85/117)and in 13 cases of mucinous adenocarcinoma was 84.62%(11/13).The expression rate of SATB2 in highly differentiated and moderately differentiated adenocarcinoma was significantly higher than in poorly differentiated adenocarcinoma(P<0.05).The positive expression rate in 53 cases of ovarian primary mucinous adenocarcinoma and 40 cases of ovarian metastases of colorectal adenocarcinoma were 0%(0/53)and 82.50%(33/40)respectively.Conclusions SATB2 can be used as an effective tumor marker to identify colorectal carcinoma ovarian metastases,especially for the metastasis of colorectal mucinous adenocarcinoma of the ovary.It could be a theoretical basis for clinicians to choose treatment options.